Bipolar Support Groups.com blog

Bipolar disorder evolves differently in patients who also binge eat, a study by Mayo Clinic, the Lindner Center of HOPE and the University of Minnesota found. Binge eating and obesity often are present among bipolar patients, but the mood disorder appears to take a different path in those who binge eat than it does in obese bipolar patients who do not, the researchers discovered. The findings are published online in the Journal of Affective Disorders.

Up to 4 percent of Americans have some form of bipolar illness, and of those, just under 10 percent also have binge eating disorder – a higher rate of binge eating than seen in the general population, says co-author Mark Frye, M.D., a psychiatrist and chair of the Department of Psychiatry/Psychology at Mayo Clinic in Rochester. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) update released this spring recognizes binge eating disorder as a distinct condition, he noted.

Bipolar patients who binge eat are more likely to have other mental health issues such as suicidal thoughts, psychosis, anxiety disorders and substance abuse, the study found. People with bipolar disorder who are obese but do not binge eat are more likely to have serious physical problems such as arthritis, diabetes, high blood pressure and heart disease.

It was more common for women than men with bipolar disorder to binge eat or to be obese, the study showed.

“The illness is more complicated, and then by definition how you would conceptualize how best to individualize treatment is more complicated,” Dr. Frye says. “It really underscores the importance of trying to stabilize mood, because we know when people are symptomatic of their bipolar illness their binge frequency is likely to increase. We want to work with treatments that can be helpful but not have weight gain as a significant side effect.”

The researchers used the Mayo Clinic Bipolar Biobank, a collaborative effort by Mayo Clinic, the Lindner Center of HOPE, University of Minnesota and Mayo Clinic Health System. More research is planned to see whether there is a genetic link to binge eating disorder in bipolar disease.

“Patients with bipolar disorder and binge eating disorder appear to represent a more severely ill population of bipolar patients. Identification of this subgroup of patients will help determine the underlying causes of bipolar disorder and lead to more effective and personalized treatments,” says co-author Susan McElroy, M.D., chief research officer at the Lindner Center of HOPE.

on line mental health support community @ http://www.bipolar4lifesupport.co

Researchers have discovered that five major mental disorders may be linked to the same common inherited genetic variations, according to a study published in the journal Nature Genetics.

Scientists from the Cross Disorders Group of the Psychiatric Genomic Consortium (PGC) used genome-wide genotype data in an analysis of people with five psychiatric disorders, alongside controls.

The mental health conditions monitored were:
◾Schizophrenia
◾Bipolar disorder
◾Major depressive disorder
◾Autism spectrum disorders
◾Attention-deficit hyperactivity disorder (ADHD).

Previous research from the group reported the first link between the disorders, revealing that people with these disorders were more likely to have variation within the same four chromosomal sites.

However, this most recent study has investigated the links in more detail, by using the same genome-wide information and large data sets.

The researchers analyzed genetic variation in thousands of people with each of the five disorders, and compared the genetic codes with those of people who did not have the conditions. The researchers calculated to what extent pairs of disorders were linked to the same genetic variants.

Results of the analysis showed the following overlaps in heritability between particular psychiatric disorders as a result of common genetic variation:
◾Schizophrenia and bipolar disorder – 15%
◾Bipolar disorder and depression – 10%
◾Schizophrenia and depression – 9%
◾Schizophrenia and autism – 3%.

Overall, the researchers found that common genetic variation accounted for between 17-28% of risk of all five disorders.

Naomi Wray of the University of Queensland, Australia, says:

“Since our study only looked at common gene variants, the total genetic overlap between the disorders is likely higher.

Shared variants with smaller effects, rare variants, mutations, duplications, deletions, and gene-environment interactions also contribute to these illnesses.”

The researchers say that these results, particularly the genetic evidence of the link between schizophrenia and depression, may have important implications for diagnostics and research.

The study was part-funded by the National Institutes of Health (NIH). Bruce Cuthbert, director of the National Institute of Mental Health, says:

“Such evidence quantifying shared genetic risk factors among traditional psychiatric diagnoses will help us move toward classification that will be more faithful to nature.”

The researchers note that although the study results “attach numbers” to molecular evidence showing the importance of heritability linked to common genetic variation that causes these five psychiatric disorders, much of the inherited genetic contribution to these disorders is unexplained, as are non-inherited genetic factors.

The study authors provide an example of how common genetic variation accounts for 23% of schizophrenia patients, and evidence from twin and family studies estimate schizophrenia’s total heritability at 81%.

Thomas Lehner, chief of the genomics research branch at the National Institute of Mental Health, says:

“It is encouraging that the estimates of genetic contributions to mental disorders trace those from more traditional family and twin studies. The study points to a future of active gene discovery for mental disorders.”

Written by Honor Whiteman

on line support community @ http://www.bipolar4lifesupport.co

Scientists say new brain imaging methods that measure blood flow could help diagnose bipolar disorder in its early stages, as well as differentiate it from depression, according to a study published in the British Journal of Psychiatry.

Researchers from the University of Pittsburgh analyzed 44 females for the study. Of these, 18 had bipolar-I disorder, 18 had unipolar depression and 18 served as a control group, with no form of mood disorder or depression.

The researchers carefully matched the women for demographic and clinical variables and the women were all experiencing an episode of depression throughout the study assessment.

Using a new imaging method called “Arterial Spin Labeling,” the researchers were able to measure the participants’ blood flow in order to monitor the brain regions linked to depression.

This new imaging method revealed an 81% accuracy in determining which women suffered from bipolar and which women had unipolar depression.

Another new method was also used, called “Pattern Recognition Analysis,” which enables the researchers to monitor brain differences specific to each individual.

Dr. Jorge Almeida, assistant professor of psychiatry at the University of Pittsburgh, says:

“Earlier and more accurate diagnoses can make an enormous difference for patients and their families, and may even save lives.

This is a very promising finding that highlights the usefulness of neuroimaging to help identify biological markers associated with different mental health conditions.”

According to the National Institute of Mental Health, bipolar disorder affects around 5.7 million adults in the US.

Research has shown that bipolar disorder has higher prevalence in the US than any other country, with 4% prevalence compared with the worldwide average of 2%.

The disorder is not easy to diagnose, as symptoms such as mood changes and lack of energy and activity levels can frequently be diagnosed as other problems. The researchers add that a fifth of people with bipolar disorder are incorrectly diagnosed when first assessed by a physician – an accurate diagnosis can take up to 10 years.

“These results also suggest that we may one day be able to predict future bipolar behavior in younger adults who haven’t shown any symptoms, allowing for earlier and more accurate treatment,” adds Dr. Almeida.

The researchers say that these two new technologies will now be used to conduct research in larger samples and in a multi-center study.

Written by Honor Whiteman

on line support community @ http://www.bipolar4lifesupport.co

We live in the most exciting and unsettling period in the history of psychiatry since Freud started talking about sex in public.

On the one hand, the American Psychiatric Association has introduced the fifth iteration of the psychiatric diagnostic manual, DSM-V, representing the current best effort of the brightest clinical minds in psychiatry to categorize the enormously complex pattern of human emotional, cognitive, and behavioral problems. On the other hand, in new and profound ways, neuroscience and genetics research in psychiatry are yielding insights that challenge the traditional diagnostic schema that have long been at the core of the field.

“Our current diagnostic system, DSM-V represents a very reasonable attempt to classify patients by their symptoms. Symptoms are an extremely important part of all medical diagnoses, but imagine how limited we would be if we categorized all forms of pneumonia as ‘coughing disease,” commented Dr. John Krystal, Editor of Biological Psychiatry.

A paper by Sabin Khadka and colleagues that appears in the September 15th issue of Biological Psychiatry advances the discussion of one of these roiling psychiatric diagnostic dilemmas.

One of the core hypotheses is that schizophrenia and bipolar disorder are distinct scientific entities. Emil Kraepelin, credited by many as the father of modern scientific psychiatry, was the first to draw a distinction between dementia praecox (schizophrenia) and manic depression (bipolar disorder) in the late 19th century based on the behavioral profiles of these syndromes. Yet, patients within each diagnosis can have a wide variation of symptoms, some symptoms appear to be in common across these diagnoses, and antipsychotic medications used to treat schizophrenia are very commonly prescribed to patients with bipolar disorder.

But at the level of brain circuit function, do schizophrenia and bipolar differ primarily by degree or are there clear categorical differences? To answer this question, researchers from a large collaborative project called BSNIP looked at a large sample of patients diagnosed with schizophrenia or bipolar disorder, their healthy relatives, and healthy people without a family history of psychiatric disorder.

They used a specialized analysis technique to evaluate the data from their multi-site study, which revealed abnormalities within seven different brain networks. Generally speaking, they found that schizophrenia and bipolar disorder showed similar disturbances in cortical circuit function. When differences emerged between these two disorders, it was usually because schizophrenia appeared to be a more severe disease. In other words, individuals with schizophrenia had abnormalities that were larger or affected more brain regions. Their healthy relatives showed subtle alterations that fell between the healthy comparison group and the patient groups.

The authors highlight the possibility that there is a continuous spectrum of circuit dysfunction, spanning from individuals without any familial association with schizophrenia or bipolar to patients carrying these diagnoses. “These findings might serve as useful biological markers of psychotic illnesses in general,” said Khadka.

Krystal agreed, adding, “It is evident that neither our genomes nor our brains have read DSM-V in that there are links across disorders that we had not previously imagined. These links suggest that new ways of organizing patients will emerge once we understand both the genetics and neural circuitry of psychiatric disorders sufficiently.”

on line support community @ http://www.bipolar4lifesupport.co

Experiments with neutrons at the Technische Universitat Munchen (TUM) show that the antidepressant lithium accumulates more strongly in white matter of the brain than in grey matter. This leads to the conclusion that it works differently from synthetic psychotropic drugs. The tissue samples were examined at the Research Neutron Source Heinz Maier-Leibnitz (FRM II) with the aim of developing a better understanding of the effects this substance has on the human psyche.

At present lithium is most popular for its use in rechargeable batteries. But for decades now, lithium has also been used to treat various psychological diseases such as depressions, manias and bipolar disorders. But, the exact biological mode of action in certain brain regions has hardly been understood. It is well known that lithium lightens moods and reduces aggression potential.

Because it is so hard to dose, doctors have been reluctant to prescribe this “universal drug”. Nonetheless, a number of international studies have shown that a higher natural lithium content in drinking water leads to a lower suicide rate in the general population. Lithium accumulates in the brains of untreated people, too. This means that lithium, which has so far been regarded as unimportant, could be an essential trace element for humans.

Lithium detection with neutrons

This is what Josef Lichtinger is studying in his doctoral thesis at the Chair for Hadron and Nuclear Physics (E12) at the Technische Universität München. From the Institute for Forensic Medicine at the Ludwig-Maximilians-Universität Munich (LMU) he received tissue samples taken from patients treated with lithium, untreated patients and healthy test persons. The physicist exposed these to a focused cold neutron beam of greatest intensity at the measuring station for prompt gamma activation analysis at FRM II.

Lithium reacts with neutrons in a very specific manner and decays to a helium and a tritium atom. Using a special detector developed by Josef Lichtinger, traces as low as 0.45 nanograms of lithium per gram of tissue can be measured. “It is impossible to make measurements as precise as those using the neutrons with any other method,” says Jutta Schöpfer, forensic scientist at the LMU in charge of several research projects on lithium distribution in the human body.

Lithium concentrates at the nerve-tracts

Lichtinger’s results are surprising: Only in the samples of a depressive patient treated with lithium did he observe a higher accumulation of lithium in the so-called white matter. This is the area in the brain where nerve tracts run. The lithium content in the neighboring grey matter was 3 to 4 times lower. Lithium accumulation in white matter was not observed in a number of untreated depressive patients. This points to the fact that lithium does not work in the space between nerve cells, like other psychotropic drugs, but within the nerve tracts themselves.

In a next step Josef Lichtinger plans to examine further tissue samples at TUM’s Research Neutron Source in order to confirm and expand his results. The goal is a space-resolved map showing lithium accumulation in the brain of a healthy and a depressive patient. This would allow the universal drug lithium to be prescribed for psychological disorders with greater precision and control. The project is funded by the German Research Foundation (DFG).

on line support community @ http://www.bipolar4lifesupport.co

A study published in the American Journal of Psychiatry suggests an association between smoking during pregnancy and increased risk for developing bipolar disorder (BD) in adult children. Researchers at the New York State Psychiatric Institute and the Department of Epidemiology at the Mailman School of Public Health at Columbia University, in collaboration with scientists at the Kaiser Permanente Division of Research in Oakland, California, evaluated offspring from a large cohort of pregnant women who participated in the Child Health and Development Study (CHDS) from 1959-1966. The study was based on 79 cases and 654 comparison subjects. Maternal smoking during pregnancy was associated with a twofold increased risk of BD in their offspring.

Smoking during pregnancy is known to contribute to significant problems in utero and following birth, including low birth weight and attentional difficulties. This is the first study to suggest an association between prenatal tobacco exposure and BD, a serious psychiatric illness marked by significant shifts in mood that alternate between periods of depression and mania. Symptoms typically become noticeable in the late teens or early adulthood.

“These findings underscore the value of ongoing public health education on the potentially debilitating, and largely preventable, consequences that smoking may have on children over time,” said Alan Brown, MD, MPH, senior author and Professor of Clinical Psychiatry and Epidemiology at the New York State Psychiatric Institute, Columbia University and Mailman School of Public Health.

The authors wrote: “Much of the psychopathology associated with prenatal tobacco exposure clusters around the ‘externalizing’ spectrum, which includes attention deficit hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), conduct disorder (CD), and substance abuse disorders. Although not diagnostically classified along the externalizing spectrum, BD shares a number of clinical characteristics with these disorders, including inattention, irritability, loss of self-control, and proclivity to drug/alcohol use.” In effect, children who were exposed to tobacco smoke in utero may exhibit some symptoms and behaviors that are found in BD.

A previous study by Dr. Brown and colleagues found that flu virus in pregnant mothers was associated with a fourfold increased risk that their child would develop BD.

on line support community @ http://www.bipolar4lifesupport.co

A study published in the October 2013 issue of the Journal of the American Academy of Child and Adolescent Psychiatry found that approximately one in three teens with bipolar disorder developed substance abuse, for the first time, during 4 years of follow-up. The study also identified several risk factors that predicted who among these teens was most likely to develop substance abuse.

Using data from the Course and Outcome of Bipolar Youth (COBY) study, a group of researchers led by Dr. Benjamin Goldstein, of the University of Toronto and the University of Pittsburgh, examined 167 youth, ages 12-17 years, to document the frequency and possible predictors of first-onset substance abuse. Participants in the study were interviewed an average of 7 times over the course of 4 years in order to examine their symptoms, functioning, stressors, and treatment.

The study found that 32% of adolescents in COBY developed abuse or dependence of alcohol or drugs, on average 2.7 years from the start of the study. Repeated experimentation with alcohol at the start of the study was the single strongest predictor of later substance abuse, although experimentation with cannabis also predicted later substance abuse. Five other factors present at the start of the study also predicted later substance abuse: oppositional defiant disorder, panic disorder, family history of substance abuse, low family cohesiveness, and absence of antidepressant treatment. Among teens with 3 or more risk factors, 54.7% went on to develop substance abuse, compared to 14.1% of teens with 0-2 risk factors.

The COBY study, funded by the National Institute of Mental Health, is the largest longitudinal study of children and adolescents with bipolar disorder. The 3-site study enrolled participants at Brown University, UCLA, and the University of Pittsburgh. COBY is continuing to follow these adolescents into their twenties and thirties.

Dr. Goldstein highlighted the risk associated with experimental substance use “in the case of adolescents with bipolar disorder, even so-called recreational substance use is playing with fire.” He concluded “we appear to have this window of 2-3 years during which we can attempt to prevent substance abuse in these youth. This study provides some clues regarding the types of preventive strategies that may be useful.”

on line support community @ http://www.bipolar4lifesupport.co

Investigators at The Feinstein Institute for Medical Research have discovered a new genetic risk factor for schizophrenia and bipolar disorder called NDST3. The findings are published online in Nature Communications.

The study, by a team lead by Todd Lencz, PhD, associate investigator at the Zucker Hillside Hospital Department of Psychiatry Research and Feinstein Institute, studied more than 25,000 individuals. In collaboration with Ariel Darvasi, PhD, of the Hebrew University of Jerusalem, Dr. Lencz has been working with a set of DNA samples from patients with schizophrenia and healthy volunteers drawn from the Ashkenazi Jewish population. The Ashkenazi Jewish population represents a unique population for study because of its short (less than 1,000-year) history and limited population. This history results in a more uniform genetic background in which to identify disease-related variants.

“This study again demonstrates the value of our Ashkenazi cohort,” said Dr. Lencz. “It is notable that the genetic variant was replicated in samples of various ethnicities from all around the world, but the effects were strongest in the Ashkenazi cohort, presumably due to their unique genetic history.”

Dr. Lencz’s team reported that the genetic variant, which changes a single “letter” of the DNA code, alters the expression of the gene NDST3. This gene is critical to neurodevelopmental processes such as axon formation and synaptic function. These findings shed new light on the genetic architecture and potential therapeutic targets for the treatment of psychiatric disease.

Schizophrenia and bipolar disorder are severe psychiatric disorders that affect 1-4 percent of the global population. Studies have shown that the two disorders are likely to have a large overlap in genetic risk factors, but only a small portion of this genetic risk has been identified.

This work was supported by a grant from the National Institute of Mental Health (NIMH), funded as part of the American Recovery and Reinvestment Act of 2009 (also known as the economic stimulus plan). More recently, the work by Drs. Lencz and Darvasi with the Ashkenazi schizophrenia cohort has received an additional $3 million from the NIMH, as well as grants from the Brain & Behavior Foundation and the Binational Science Foundation.

Dr. Lencz is also the co-leader of The Ashkenazi Genomics Consortium, a collaborative effort involving more than a dozen investigators from leading institutions (including Columbia University, Mt. Sinai School of Medicine, Albert Einstein College of Medicine and MIT), using similar strategies to understand the genetic basis of diseases including cancer, diabetes, and Parkinson’s.

on line mental health community @ http://www.bipolar4lifesupport.co

The use of antidepressants in the treatment of bipolar disorder remains controversial. Some studies and treatment guidelines suggest that antidepressant treatment for bipolar disorder may have the potential to increase the manic switch, while others recommend short-term antidepressant treatment and early discontinuation. A recent study by Dr. Yingli Zhang and co-workers from Mental Health Institute of Central South University in China involved new large-sample double-blind randomized controlled trials, excluded open-label design studies, and supplemented studies involving homogeneous patients. Suicidality firstly served as an important outcome, strict inclusion criteria included limitation to double-blind randomized controlled studies and interventional treatment without use of antipsychotics to make the study results more objective and convincing. The results from this study do not support that antidepressants are more effective in the treatment of bipolar disorder. Antidepressants are not superior to placebo and other medication in short-term, and long-term use of antidepressants cannot achieve higher response and remission rates of bipolar disorder. These findings, published in the Neural Regeneration Research (Vol. 8, No. 31, 2013), guide future clinical studies and provide evidence for preparing treatment strategy for bipolar disorder.

on line support community @ http://www.bipolar4lifesupport.co

Famous people with bipolar disorder

Below is a list of some famous people who suffer or suffered from bipolar disorder:
◾Adam Ant, British musician
◾Amy Winehouse, British musician
◾Axl Rose, lead singer for Guns N’ Roses
◾Catherine Zeta-Jones, British (Welsh) actress
◾Edgar Allan Poe, British poet and writer (most likely had bipolar disorder)
◾Edward Elgar, British composer
◾Florence Nightingale, British nurse and health campaigner
◾Frank Bruno, boxer
◾Frank Sinatra, American singer and actor
◾Graham Greene, British novelist
◾Jack Irons, drummer, formerly of Red Hot Chili Peppers
◾Jack London, American author
◾Jean-Claude Van Damme, Belgian actor
◾Ludwig van Beethoven, German composer and pianist (possibly have had bipolar disorder)
◾Maria Bamford, American comedian
◾Mel Gibson, Australian actor and director
◾Rep. Patrick J. Kennedy, American politician
◾Richard Dreyfuss, actor
◾Robert Downey, Jr., actor
◾Sting, British musician
◾Sidney Sheldon, American producer, writer
◾Sinéad O’Connor, Irish musician
◾Spike Milligan, Irish comedian
◾Stephen Fry, British actor, comedian and writer
◾Vincent Crane, keyboard player of Atomic Rooster
◾Vincent Van Gogh, Dutch artist (possibly had bipolar disorder; there are various hypotheses)
◾Virginia Woolf, British writer
◾Vivien Leigh, British actress.

on line mental health support community @ http://www.bipolar4lifesupport.co